Continuous androgen deprivation in stage C and D prostate cancer: Could the treatment be suspended?

4745 Purpose To evaluate whether patients (pts) with advanced prostate cancer (APC), programmed for continuous androgen deprivation (CAD), could suspend the treatment when stable clinical and biological response (BCR) has been achieved since at least 30 months. Methods BCR was defined as follows: PSA value not exceeding 0.5 ng/ml, normal findings on prostate digital rectal examination (DRE), no dysuria. Following informed consent we proposed suspension CAD to pts in BCR for at least 30 months, in alternative to prolong the treatment until disease progression. Reintroduction of androgen deprivation was planned in case of: PSA value exceeding 10 ng/ml, positive prostate DRE, symptoms of disease. Results out of 184 consecutive pts with APC, 49 pts in BCR were identified and 46 accepted the proposal of suspending CAD. Median age 78 (range 60 to 91); 15 (31%) stage C, 7 (15%) stage D1, 24 (53%) stage D2. The median duration of treatment before suspension has been 36.8 months (range 28.5 to 78.6) (CI 95% 36 to ...